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The expression of angiogenic factors, such as the vas-
cular endothelial growth factor (VEGF) subtypes and 
their receptors (VEGF-Rs), is upregulated on vascular 
endothelial cells during tumour angiogenesis. Previous 
studies demonstrated that these angiogenetic factors are 
major contributors to the growth in different malignant 
tumours (1). However, the role of these markers on the 
clinical follow-up and disease-prognosis in malignant 
melanoma (MM) remains unclear (1, 2). This study aimed 
to dissect the main associations between VEGF subtypes 
and receptors, patients’ characteristics and prognosis in a 
group of patients with MM.
METHODS
This was a subsequent analysis on a cohort of adult patients with 
primary or metastatic MM seen at the dermatology outpatient of 
Inselspital University Hospital of Bern (Switzerland) between 
2003 and 2015, with a mean ± standard deviation (SD) follow-up 
of 6.5 ± 4.6 years. The methods and characteristics of the study 
population were described elsewhere (1). Patients with melano-
cytic naevus or with uncomplete VEGF characterization or without 
complete follow-up were not included in this analysis. The study 
was done in agreement with the Declaration of Helsinki and was 
approved by the local Ethics Committee.
For analysis purposes, a selection of clinically relevant variables 
was considered. These included: demographics, tumour location 
and type, Breslow thickness, presence of ulceration and metastatic 
MM, sentinel lymph node (SLN) findings and VEGF subtypes 
detected by using next-generation tissue microarray (ngTMA) as 
described before (1).  In addition, we included overall (OS) and 
disease-free survival (DFS) up to 15 years of follow-up.
Statistical analysis 
Associations among factors were investigated by using an algo-
rithm that is able to display the best connections between variab-
les taking into account other covariates in the system (3, 4). For 
analysis purposes, continuous variables were categorized by using 
clinically meaningful thresholds or, for VEGF subtypes, optimal 
cut-offs based on correlation with OS (1). Multiple generalized 
linear models (GLMs) with elastic net regularization were then 
fitted by taking each time, sequentially, a variable as the outcome 
and the others as covariates. Binomial and Poisson distributions 
were assumed for binary and survival outcomes, respectively. 
Relaxation of elastic net estimates was also used to get unbiased 
regression coefficients (5). Finally, in order to have comparable 
coefficients, log relative risks were converted to log odds ratios 
by using an approximation formula (6). System weights were 
then computed by using inverse exponential transformation on 
regression coefficients (3). The maximum spanning tree (MST) 
filter (7), was then applied to the matrix of weights and a semantic 
connectivity map was generated. In the map straight lines show the 
strongest connections while spatial proximity between variables 
indicate patterns of direct correlations. The analysis was perfor-
med with MATLAB v.9.2 (The MathWorks, Natick, MA, USA).
RESULTS
Overall 137 patients with MM were included in the study 
(60.0% men, mean age 62.3 ± 15.8 years) (Table SI1). 
Metastatic MM was present in 37.2% of patients. These 
patients were followed-up for a mean ± SD of 6.1 ± 6.6 vs. 
6.8 ± 2.9 years for those without metastasis. Characteristics 
of VEGF subtypes are described in Table SII1. Regarding 
survival outcomes, cumulative OS and DFS were 67.5% 
and 50.0%, respectively, at 15 years.
Low and high values of VEGF subtypes were distin-
guished in two clusters in the map (Fig. 1). In particular, 
high values of VEGF, especially VEGF-C, were directly 
associated with thick MM, which was linked to DFS and 
ulceration. DFS was also strongly connected to metastatic 
MM and head/neck localisation. OS was also in the same 
area and associated with positive SLN, nodular MM and 
ulceration. In addition, intermediate Breslow thickness, 
MM on the trunk and male sex were connected with high 
values of VEGF-D, VEGF-R1 and VEGF-R3. Looking at 
the connections among high values of VEGF, there was a 
close linking between VEGF-C, VEGF-R2 and VEGF-R3 
and between VEGF-B, VEGF-A and VEGF-R1. VEGF-D 
was also strongly connected to VEGF-C and separated 
from other subtypes. Conversely, low values of VEGF, 
especially VEGF-C and VEGF-R3, were connected to 
LMM, thin MM and SSM. In addition, presence of MM on 
limbs, age < 50 years and females were also in this area and 
linked to VEGF-C and VEGF-D. When excluding patients 
with metastatic MM, high values of VEGF-C were still as-
sociated with decreased DFS (data not shown). However, 
it was not clear from our data whether this holds also for 
patients with thin MM.
DISCUSSION
In this study, a close linking between VEGF-C, VEGF-R2 
and VEGF-R3 has been shown. Previous research has also 
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3374
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shown that VEGF-C could be involved in lymphatic hy-
perplasia and metastatic lymph nodes spread by activating 
VEGFR-2 and VEGFR-3 (1, 8–10). Increasing evidence 
shows a specific role of VEGF-C and VEGF-R3 in tumour 
lymphangiogenesis and lymphatic metastasis in multiple 
malignancies (1, 8–10) Recent studies have revealed a 
positive association between VEGF-C expression and 
both progression stage and lymph node metastasis (1, 8, 
11). In our study high values of VEGF-C were directly 
associated with thick MM, which was connected to many 
other prognostic factors. In fact, the VEGF-C/VEGFR-3 
axis plays an important role in inducing enlargement of 
peritumoural lymphatic vessels and increasing lymph 
flow, which promotes lymphatic invasion and lymph node 
metastasis (1, 8, 11). Furthermore, VEGF-C participates 
in tumour cell chemotaxis, which is an independent, yet 
interlinked and important step in the process of cancer 
metastasis (1, 8, 9, 11). In similar studies VEGF-C expres-
sion was found significantly increased in metastatic MM 
compared to non-metastatic MM (1, 12–14).
One possible limitation of this study was a technical limit 
during the preparation of TMAs as described elsewhere 
(1). Furthermore, the analysis was mainly exploratory and 
specific hypotheses emerging from the map should be better 
tested in further ad hoc studies. Another limitation was the 
relatively low number of patients included in the analysis, 
which does not allow generalization of results.
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Fig. 1 Semantic map showing the best linking among selected variables in the 
study population. The numbers on connecting lines indicate normalized correlations 
(between 0 and 1). The line thickness corresponds to the strength of association (thin line 
<0.6; medium line 0.6–0.79; thick line ≥0.8). DFS: disease-free survival; hi: high; lo: 
low; LMM: lentigo malignant melanoma; MM: malignant melanoma; OS: overall survival; 
SLN: sentinel lymph node; SSM: superficial spreading melanoma; thick: thickness; VEGF: 
vascular endothelial growth factor.
